Carla Strina

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

Katharina Feldinger, Daniele Generali, Gabriela Krämer-Marek et al. · Oncotarget · 2014 · 88 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Giovanni Allevi, Carla Strina, Daniele Andreis et al. · British Journal of Cancer · 2013 · 86 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

Vittorio Ferrari, Francesca Valcamonico, Vito Amoroso et al. · Cancer Chemotherapy and Pharmacology · 2005 · 79 citations

Medicine, Oncology, Pharmacology +12

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

Siti Norasikin Mohd Nafi, Daniele Generali, Gabriela Krämer-Marek et al. · Oncotarget · 2014 · 64 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

L. Provenzano, M.V. Dieci, G. Curigliano et al. · Annals of Oncology · 2025 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16